Needham & Company LLC Issues Pessimistic Forecast for Alphatec (NASDAQ:ATEC) Stock Price

Alphatec (NASDAQ:ATEC) had its price objective lowered by analysts at Needham & Company LLC from $25.00 to $14.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the medical technology company’s stock. Needham & Company LLC’s price target points to a potential upside of 36.85% from the stock’s current price.

A number of other equities analysts have also commented on ATEC. TD Cowen reaffirmed a “buy” rating on shares of Alphatec in a report on Tuesday, January 27th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a report on Friday, March 27th. Lake Street Capital reissued a “buy” rating on shares of Alphatec in a research note on Wednesday, February 25th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Finally, Wells Fargo & Company raised Alphatec to a “strong-buy” rating in a research note on Wednesday, March 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $22.09.

Alphatec Price Performance

Alphatec stock opened at $10.23 on Wednesday. Alphatec has a one year low of $9.11 and a one year high of $23.29. The business has a fifty day moving average price of $11.73 and a 200-day moving average price of $15.95. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. The firm has a market capitalization of $1.57 billion, a P/E ratio of -10.77 and a beta of 0.96.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.21). The firm had revenue of $192.11 million during the quarter, compared to analysts’ expectations of $197.51 million. During the same period in the prior year, the firm earned ($0.35) earnings per share. Alphatec’s revenue for the quarter was up 13.6% on a year-over-year basis. As a group, equities research analysts forecast that Alphatec will post -0.28 EPS for the current year.

Insiders Place Their Bets

In related news, General Counsel Tyson Eliot Marshall sold 88,835 shares of Alphatec stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $12.49, for a total transaction of $1,109,549.15. Following the completion of the sale, the general counsel owned 559,459 shares of the company’s stock, valued at approximately $6,987,642.91. This trade represents a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Scott Lish sold 260,535 shares of Alphatec stock in a transaction on Friday, March 13th. The shares were sold at an average price of $12.30, for a total value of $3,204,580.50. Following the sale, the chief operating officer directly owned 815,704 shares of the company’s stock, valued at $10,033,159.20. This represents a 24.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 689,614 shares of company stock worth $8,634,850 over the last three months. Corporate insiders own 22.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ATEC. Millennium Management LLC increased its holdings in shares of Alphatec by 292.2% in the fourth quarter. Millennium Management LLC now owns 2,225,927 shares of the medical technology company’s stock worth $46,834,000 after buying an additional 1,658,349 shares during the period. Iron Triangle Partners LP purchased a new position in shares of Alphatec in the fourth quarter worth about $27,051,000. Morgan Stanley increased its holdings in shares of Alphatec by 22.0% in the fourth quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company’s stock worth $91,333,000 after buying an additional 784,191 shares during the period. Tudor Investment Corp ET AL increased its holdings in shares of Alphatec by 608.4% in the third quarter. Tudor Investment Corp ET AL now owns 900,491 shares of the medical technology company’s stock worth $13,093,000 after buying an additional 773,367 shares during the period. Finally, M&G PLC purchased a new position in shares of Alphatec in the fourth quarter worth about $14,055,000. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec News Summary

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Management reiterated a bullish 2026 operating outlook: forecasts roughly $882M in 2026 revenue while keeping adjusted EBITDA at $134M, signaling confidence in near‑term growth and profitability execution. Alphatec forecasts $882M 2026 revenue
• Positive Sentiment: Alphatec secured a new senior secured syndicated credit facility (improves liquidity and funding capacity for growth initiatives and working capital). This reduces refinancing risk and supports execution of the 2026 plan. Alphatec Establishes New Syndicated Credit Facility for Growth
• Positive Sentiment: On a per‑share basis the company reported break‑even EPS for Q1 versus expectations for a small loss, a material improvement from last year’s loss and evidence operating leverage is improving. Alphatec (ATEC) Reports Break-Even Earnings for Q1
• Positive Sentiment: Q1 gross margins remain strong (GAAP ~71%, non‑GAAP ~72%) and revenue grew ~13.6% YoY — constructive for long‑term margin expansion if top‑line momentum holds. ATEC Reports First Quarter Financial Results
• Neutral Sentiment: Full Q1 earnings call transcript provides color on product trends, backlog and margin drivers — worth reviewing for guidance detail and surgeon adoption commentary. Alphatec Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 EPS missed the consensus (reported ($0.22) vs. est. ($0.01)) and revenue slightly missed estimates ($192.11M vs. $197.51M), which prompted selling pressure as investors punished the surprise miss. Alphatec Q1 Earnings and Results
• Negative Sentiment: A notable institutional position disclosed it trimmed/sold roughly $18M of Alphatec stock last quarter — and coverage noted the stock plunged ~20% after the earnings print, amplifying near‑term downside via forced or momentum selling. This Fund Disclosed Selling $18 Million in Alphatec

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.